Clinical studies on Bowtrol IBS Treatment
|
People suffering from IBS understand how such condition can hinder their social and practical life and affect it harmfully. You cannot depend on unreliable products; therefore, we brought to your attention, some scientific and clinical studies that have been conducted on our product to prove that we do no rely on uncertain scientific information, but on a very solid scientific fact that can guide us toward the best benefits without passing through any ugly unhealthy side effects. Our customers have been fully confident in this product, to the extend that we never received any complains, the product is totally natural so no chance for serious side effect. With each of this product, you can solve your problem fundamentally and if you condition is much severe you can combine them together and you will have the most powerful tool against IBS that will help you move on with your life naturally. |
Probiotic Formula eliminates Irritable Bowel syndrome symptoms
DATE: April 2005 - DSIB
New York:
Bowtrol with Probiotic preparations has relieved patients suffering from IBS condition; a study that was published in March has reviled this fact. The study was conducted by Irish scientists on 77 patients with IBS symptoms, were divided into 2 main groups, the first will be subjected to B. infantis, (Lactobacillus salivarius) and the second will take placebo. The study monitored the chain in 8 weeks. And recorded the changes daily. B. infantis patients has showed much smoother and better stool formation and reduction in pain and bloating. An interesting finding revealed that Bowtrol had an immune modulating role, since it can normalize Proinflammatory response Th-1. Bowtrol has shown to be excellent competitor to known pharmaceutical drugs for IBS symptoms such as Zelnorm and Lotronex.
Gastro-intestinal and associated effects ( L. Sporogenes)
Clinical studies on Bowtrol have been conducted in different hospitals. The results from all these hospitals will be present in table 5.1. All the studies will indicate that taking L. sorogenes can significantly improve the condition, and enhance better intestinal movement and reduce allergies or disorders. Allergy was thought to be related to improper presence of intestinal flora.
SUMMARY OF SELECTED CLINICAL REPORTS FROM JAPAN : TRIALS WITH LACBONÒ (L. Sporogenes)
1. Condition: Acute and Chronic intestinal catarrh.
Groups of 38 individuals were subjected to 100-600 million spores per day in doses for a period of time that ranges from 2-12 days. The results showed 86.8% of the subject cases has showed reduction or elimination in their symptoms.
Conclusion: the study indicates recover from diarrhea and reduction in all accompanying symptoms such as anorexia.
2. Condition: Diarrhea
Group of 15 suffering patients, were subjected to 75-600 million spores per day in doses divided into 3-12 days, the results showed 100 % efficiency and full recovery from diarrhea. Normal stool was obtained from day 3-4.
3. Condition: Constipation
Group of 10 individuals were subjected to 300-750 million spores per day in doses divided through 2-10 days. The results indicated 70.0% of the patients to recover into normal stool.
4. Condition: Abnormal intestinal fermentation
Group of 9 individuals. Were subjected to 300-600 million spores per day, in doses divided into 4-14 days. The results reveal 100% efficiency. Complete disappearance of all the mal symptoms such as vomiting, nausea, lackness of appetite in addition normal stool production with absence of stomachaches and diarrhea.
5. Condition: Dyspepsia infantum
Group of 26 individuals were subjected to 100-200 million spore per day in doses divided into 1-17 day. Results indicate 84.7% efficiency. In general stool formation and texture has improved the frequency of excretion was reduced to half or even less than before treatment.
6. Condition: Allergic skin diseases
Group of 5 people, were subjected to 200-450 million spores per day in doses divided among 4-12 days. The results indicates 80.0% efficiency with significant reduction in conditions such a strophulus and eczema. Results were obvious from day 3.
7. Condition: Miscellaneous symptoms
Group of 10 individuals were subjected to 20-50 million spores per day in doses divided among 4-20 days. The study indicates 80% efficiency. Incredible results were monitored in cases such as Anorexia.
The above data are cited from clinical reports by: Terumichi Kuniya, Pediatric Clinic of Shinko Hospital, Kobe; Jetsuo Nitta, Medical Clinic of Kugason Hospital; Goro Koide, Pediatric Clinic of Kanto Teishin Hospital; Michio Ogasawara, Medical Clinic of Kahoku Hospital; Susumu Nakazawa, Pediatric Clinic of Ebara Hospital.
In a study on L. sporogenes ( SPORLAC Ò 59) in India. A group of 60 neonatal cases with diarrhea symptoms with a rate higher than 6 were subjected to sporlac treatment. The suggested and recommended dose was 5 million spores per kilogram of body weight. The neonates had in addition to diarrhea other conditions. Such as jaundice septicemia and Cord infection in the next manner.
| Jaundice | 3 |
| Septicemia | 3 |
| Cord Infection | 3 |
| Vomiting | 3 |
80% of the neonates already have been subjected to breast-feeding. around 19 % were breast and bottle fed, and only 1% did not experience breast feeding and only were bottle fed. Recovery was monitored in a range from 1-3 days.
| Condition | Cases treated | Cases Cured | Success rate |
| Diarrhea | 60 | 49 | 81.7% |
| Constipation | 3 | 3 | 100% |
| Jaundice | 3 | 3 | 100% |
If we compare the results from SPORLAC to the normal practice in treating diarrhea cases by applying antibiotics and antidiarrheal mixtures we may favor the first since it has no side effects, we can reach results within 1.8 days in average. These studies are supported by similar ones conducted in Japan cited in 59 and results showed that 78.4% of the SPORLAC treatment for infantile diarrhea showed elimination in symptoms. In India, a much earlier study done by Mathur et. al. has indicated that the average time for recovery is 2-3 days.
Other Clinical Trial References:
Krivenko V.V., Potebnia G.P., Loiko V.V. ( 1989). Experience in treating
digestive organ diseases with medicinal plants. Vrach Delo.
March(3):76-8
Achterrah-Tuckermann U., Kunde R., Flaskamp E., Isaac O., Thiemer K.
(1980). Pharmacological investigations with compounds of chamomile. 5.
Investigations on the spasmolytic effect of compounds of chamomile and
kamillosan on the isolated guinea-pig ileum. Planta Medica 39(1):38-50
Mann, C. and E.J. Staba. 1986. The Chemistry, Pharmacology, and
Commercial Formulations of Chamomile. In L. E. Craker and J. E. Simon,
eds. Herbs, Spices, and Medicinal Plants: Recent Advances in Botany,
Horticulture, and Pharmacology. Vol. 1. Phoenix, AZ: Oryx Press. Pp.
235-280
Mariann S., Gizella V.P., Ede F. (1976). Antifungal effect of the
biologically active components of Matricaria chamomilla L. Acta Pharm
Hung. 46(5-6):232- 47
Choi E.M., Hwang J.K. (2004). Antiinflammatory, analgesic and
antioxidant activities of the fruit of Foeniculum vulgare. Fitoterapia.
75(6):557-65.
Yamahara, et. al. 1990. Gastrointestinal Motility Enhancing Effect of
Ginger and its Active Constituents. Chem. Pharm. Bull. 38(2):430-431.
Mustafa T., Srivastava K.C., Jensen K.B. (1993) .Drug development
report: 9. Pharmacology of ginger, Zingiber officinale. Journal of Drug
Development 6(1) : 25-39
Chevallier. A. The Encyclopedia of Medicinal Plants Dorling Kindersley.
London 1996 ISBN 9-780751-303148
Baschetti, R., New Zealand Medical Journal, April 26, 156-157, 1995
Grigoleit H.G., Grigoleit P. (2005). Peppermint oil in irritable bowel
syndrome. Phytomedicine12(8):601-6.